Vista­gen's pos­i­tive PhI­II for so­cial anx­i­ety nasal spray push­es stock price up 1,000+%

San Fran­cis­co-based Vista­gen saw its stock soar more than 1,000% at one point on Mon­day af­ter un­veil­ing pos­i­tive topline re­sults from a Phase III tri­al show­ing its nasal spray helped adults with so­cial anx­i­ety dis­or­der.

The Phase III PAL­ISADE-2 tri­al of 140 sub­jects met its pri­ma­ry end­point, with the ex­per­i­men­tal drug known as fase­dienol demon­strat­ing a sta­tis­ti­cal­ly sig­nif­i­cant dif­fer­ence in av­er­age Sub­jec­tive Units of Dis­tress (SUDS) score dur­ing a pub­lic speak­ing chal­lenge, when com­pared to place­bo (p=0.015), the com­pa­ny said. Vista­gen al­so not­ed that the tri­al met its sec­ondary end­point, too, demon­strat­ing a sta­tis­ti­cal­ly sig­nif­i­cant dif­fer­ence in the pro­por­tion of clin­i­cian-as­sessed re­spon­ders be­tween fase­dienol and place­bo as mea­sured by the CGI-I scale (p=0.033).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER